SAN DIEGO, CA–December 3, 2018–Ascentage Pharma, a clinical-stage biopharmaceutical company dedicated to the development of novel therapies for the treatment of cancers, hepatitis B and aging-related diseases, today announced data from a Phase 1 clinical study of its novel BCR-ABL inhibitor, HQP1351, in patients with Tyrosine Kinase Inhibitor (TKI)-refractory chronic myelogenous leukemia (CML) at the 60th American Society of Hematology (ASH) Annual Meeting. The data were reviewed in an oral presentation by Principal Investigator Qian Jiang, M.D., Deputy Director of the Institute of Hematology at Peking University People’s Hospital.
“While certain TKIs, such as imatinib, have been effective in some cancer patients, there is an urgent need to address resistance that develops with these therapies,” said Dr. Jiang. “In this Phase 1 study, HQP1351 showed potential results in CML patients resistant to prior TKIs.”
Study Details and Highlights:
Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, commented: “HQP1351 shows potential as a third-generation BCR-ABL inhibitor. We have initiated a potential registration-enabling Phase 2 study for patients with TKI-resistant CML for HQP1351 in China and seek to expedite its development, advancing a potential new treatment for patients who have developed resistance to imatinib.”
HQP1351 is a novel kinase inhibitor developed by Ascentage Pharma. It is an oral third-generation BCR-ABL inhibitor targeting a broad spectrum of BCR-ABL mutants, including those with the T315I mutation, to treat drug-resistant CML patients. Phase 1 clinical trials for patients with imatinib-resistant CML have been completed and Phase 2 clinical trials have been initiated.
About Ascentage Pharma
Ascentage Pharma is a globally-focused clinical-stage biopharmaceutical company developing novel therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company’s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of seven clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.